Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year Low – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price hit a new 52-week low during trading on Wednesday . The stock traded as low as $17.50 and last traded at $18.41, with a volume of 421803 shares traded. The stock had previously closed at $17.91.

Analyst Ratings Changes

A number of brokerages recently weighed in on KLRA. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Leerink Partners started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 target price for the company. JPMorgan Chase & Co. started coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 target price for the company. TD Cowen started coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target on the stock. Finally, William Blair began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Performance

The firm has a market cap of $2.39 billion and a PE ratio of -0.01. The stock has a 50 day simple moving average of $20.69.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings data on Tuesday, May 26th. The company reported ($3,650.00) EPS for the quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.